Triple Negative Breast Neoplasms: all 1,163 studies

Page 4 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyRecruitingNCT06125080Phase 2
• 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast CancerRecruitingNCT06104085Not applicable
• Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA AssessmentRecruitingNCT06087120
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingNCT06084481Phase 1
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)RecruitingNCT06081244Phase 3
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCRecruitingNCT06078384Phase 2
• PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.RecruitingNCT06059469Phase 2
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 1
• Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingNCT06008275Early Phase 1
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
• A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast CancerRecruitingNCT05989828Phase 1
• Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsRecruitingNCT05985655Phase 1/2
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingNCT05983432Phase 1
• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and SurgeryRecruitingNCT05973864Phase 2
• Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical TrialNot yet recruitingNCT05957939Phase 1
• A Study of ILB2109 and Toripalimab in Patients With Advanced Solid MalignanciesRecruitingNCT05955105Phase 1/2
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeRecruitingNCT05954442Phase 3
• T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low PatientsNot yet recruitingNCT05953168Phase 2
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)Not yet recruitingNCT05928780Phase 1/2
• Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics PlatformRecruitingNCT05916755
• Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast CancerRecruitingNCT05914961
• Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerRecruitingNCT05910710
• Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)RecruitingNCT05909332Phase 3
• A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerRecruitingNCT05902988Phase 1/2
• Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With PembrolizumabRecruitingNCT05877859
• Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast CancerNot yet recruitingNCT05872412Phase 2
• PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
• Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2
• A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
• Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast CancersRecruitingNCT05846789Phase 2
• Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast CancerNot yet recruitingNCT05843292Phase 4
• Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingNCT05834582Phase 2
• TIP in Patients Affected by Metastatic TNBCRecruitingNCT05831553
• Efficacy of Interleukin-2 in Triple Negative Breast CancerNot yet recruitingNCT05821686Phase 1/2
• Grouping Immune-modulation With Cryoablation (LOGIC) for Breast CancersNot yet recruitingNCT05806385Phase 1/2
• Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast CancerRecruitingNCT05806060Phase 3
• Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyRecruitingNCT05770531Phase 2
• Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical TrialsNot yet recruitingNCT05769491
• BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT05768932Phase 1
• Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 TrialRecruitingNCT05763992Phase 2
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingNCT05760378Phase 3
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsRecruitingNCT05746897Phase 1
• Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerNot yet recruitingNCT05746728Phase 1/2
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerRecruitingNCT05741164Phase 2
• Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)RecruitingNCT05722795Not applicable
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruitingNCT05706129Phase 1/2
• Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid TumoursNot yet recruitingNCT05698238Phase 1
• A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast CancerRecruitingNCT05692661Phase 1
• Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast CancerRecruitingNCT05677802Not applicable
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)RecruitingNCT05660083Phase 2
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingNCT05633654Phase 3
• First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor MalignanciesRecruitingNCT05627960Phase 1
• Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2
• A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerRecruitingNCT05570253Phase 2
• A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingNCT05556200Phase 2
• The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast CancerRecruitingNCT05550415Phase 2
• Estrogen Receptor (ER) PET/CT Imaging in Breast CancerRecruitingNCT05541367
• Genomically Guided Radiation Therapy in the Management of Triple Negative Breast CancerRecruitingNCT05528133Phase 2
• DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast CancerRecruitingNCT05504707Phase 1
• AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
• START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerRecruitingNCT05492682Phase 1
• Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationRecruitingNCT05491226Phase 2
• Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast CancerRecruitingNCT05491083Phase 1/2
• JAB-2485 Activity in Adult Patients With Advanced Solid TumorsRecruitingNCT05490472Phase 1/2
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 2
• Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast CancerRecruitingNCT05475678Phase 2
• Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNot yet recruitingNCT05461690Phase 2
• Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILSRecruitingNCT05451784Phase 1/2
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingNCT05447702Phase 2
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingNCT05422794Phase 1
• Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to TreatmentRecruitingNCT05404321
• Role of the Immune Environment in Response to Therapy in Breast CancerRecruitingNCT05396612
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsRecruitingNCT05377996Phase 1/2
• EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast CancerRecruitingNCT05341492Early Phase 1
• Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerRecruitingNCT05329532Phase 1/2
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT05318469Phase 1/2
• Eribulin as a Second-line Treatment in Triple-negative Advanced Breast CancerRecruitingNCT05302778
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingNCT05296564Phase 1/2
• Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) SignatureRecruitingNCT05288127Phase 2
• TT-702 in Patients With Advanced Solid Tumours.RecruitingNCT05272709Phase 1/2
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1
• Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBCRecruitingNCT05192798Phase 2
• Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT05128734Phase 2
• Study of Screening Brain MRIs in Stage IV Breast CancerRecruitingNCT05115474Phase 2
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerRecruitingNCT05111561Phase 1
• A Study of NX-1607 in Adults With Advanced MalignanciesRecruitingNCT05107674Phase 1
• A Beta-only IL-2 ImmunoTherapY StudyRecruitingNCT05086692Phase 1/2
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsRecruitingNCT05076760Phase 1
• Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
• Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" StudyNot yet recruitingNCT05067530Phase 2
• The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid TumorsRecruitingNCT05037825
• Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)RecruitingNCT05035745Phase 1/2
• Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingNCT05020860Phase 2
• Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerRecruitingNCT05019690Phase 1/2
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingNCT05005403Phase 1
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRecruitingNCT04981119

← Triple Negative Breast Neoplasms overview